CSPC Pharmaceutical Group Limited (CSPCY)
OTCMKTS
· Delayed Price · Currency is USD
2.840
-0.110 (-3.73%)
May 15, 2025, 2:23 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Total Finished Drugs | 23.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Finished Drugs Growth | -7.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vitamin C | 1.99B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vitamin C Growth | 3.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Antibiotics | 1.59B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Antibiotics Growth | -7.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Bulk Products | 3.58B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Bulk Products Growth | -1.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Functional Food and Others | 1.69B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Functional Food and Others Growth | -22.18% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nervous System | 9.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nervous System Growth | 6.12% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology | 4.40B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Growth | -28.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Anti-Infectives | 4.09B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Anti-Infectives Growth | -3.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular | 2.08B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular Growth | -14.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Respiratory System | 1.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Respiratory System Growth | -23.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Digestion and Metabolism | 1.05B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Digestion and Metabolism Growth | 18.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Therapeutic Areas | 1.26B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Therapeutic Areas Growth | 0.72% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Licence Fee Income | 17.83M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Licence Fee Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Finished Drugs Segment Profit | 4.83B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Finished Drugs Segment Profit Growth | -27.95% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vitamin C Segment Profit | 211.28M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vitamin C Segment Profit Growth | 4168.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Antibiotics Segment Profit | 299.18M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Antibiotics Segment Profit Growth | 93.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Bulk Products Segment Profit | 510.45M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Bulk Products Segment Profit Growth | 220.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Functional Food and Others Segment Profit | 305.29M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Functional Food and Others Segment Profit Growth | -45.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Mainland China | 25.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Mainland China Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Asian Regions | 1.18B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Asian Regions Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 1.31B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Revenue (Pre-FY2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America | 853.04M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies | 553.88M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|